A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥60 With Poor Prognosis Acute Myeloid Leukemia (AML)

Trial Profile

A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥60 With Poor Prognosis Acute Myeloid Leukemia (AML)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Azacitidine (Primary) ; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Aug 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 07 May 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 07 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top